KalVista Pharmaceuticals, Inc. Q1 2025 Earnings Call Summary

Core Insights - The company achieved $49 million in net product revenue during the first six months of launch, driven by steady U.S. adoption and initial entry into the German market [1] - Over 1,700 patient start forms were secured, activating 724 unique prescribers, which represents approximately 20% of the estimated 9,000 U.S. HAE patients [1] - A strategic shift was observed where refills now constitute the majority of revenue, indicating sustained real-world utilization and growing confidence in oral on-demand therapy [1] Treatment Adoption - The early success is attributed to the removal of treatment barriers, allowing patients to treat more attacks earlier compared to historical 8-hour delays with injectables [1] - EKTERLY is positioned as a foundational therapy following its rapid inclusion as a first-line treatment for adolescents in international pediatric guidelines [1] Global Expansion - The company expanded its global commercial footprint through a Japanese launch with Kaken Pharmaceutical and a new distribution partnership in Latin America [1]